Skip to search
Skip to main content
Back to Search
Start Over
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Authors :
le Roux, Carel W Astrup, Arne Fujioka, Ken Greenway, Frank Lau, David C W Van Gaal, Luc Ortiz, Rafael Violante Wilding, John P H Skjøth, Trine V Manning, Linda Shapiro Pi-Sunyer, Xavier Hamann, Andreas Barakat, Alain Blüher, Matthias Linn, Thomas Mölle, Andrea Segner, Alexander Stübler, Petra Tosch-Sisting, Regina Pacini, Furio Santini, Ferruccio Marchesini, Giulio Rotella, Carlo Maria Invitti, Cecilia Vettor, Roberto Buscemi, Silvio Raya, Pedro Mezquita Freijoo, Felipe Casanueva de Barbará, Ramón Gomis Carraro, Raffaele Bobillo, Enrique Romero de la Cuesta, Carmen Farsang, Csaba Csaszar, Albert Zahorska-Markiewicz, Barbara Pupek-Musialik, Danuta Franek, Edward Ostrowska, Lucyna Olszanecka-Glinianowicz, Magdalena Lalic, Nebojsa Micic, Dragan Ludvik, Bernhard Paulweber, Bernhard Prager, Rudolf Scheen, André Van Gaal, Luc Astrup, Arne Vernon Hermansen, Kjeld Madsbad, Sten Rissanen, Aila Nieminen, Sakari Savolainen, Markku Krempf, Michel Romon, Monique Laville, Martine Marre, Michel Mira, Reginald Finucane, Francis Veenendaal, Aletha van Berkum, Frank Johannsson-Vidarsdóttir, Solrun Van de Walle, Vivienne Meesters, Eelco Hjelmesæth, Jøran Klemsdal, Tor Ole Kulseng, Bård Bach-Kliegel, Birgit Laederach, Kurt Villiger, Lukas Golay, Alain Bilz, Stefan Sathyapalan, Thozhukat Bain, Stephen Kumar, Sudesh Le Roux, Carel Wynard Lean, Michael E.J. McGowan, Barbara Rehman, Tariq Wilding, John Wittert, Gary Caterson, Ian Proietto, Joeseph Prins, John Neto, Bruno Geloneze Gross, Jorge Luiz Chacra, Antonio Roberto Halpern, Alfredo de Almeida Suplicy, Henrique Chow, Francis Chun Chung Thacker, Hemant P Chadha, Manoj Chandalia, Hemaraj Unnikrishnan, Ambika Kalra, Sanjay Deshpande, Neeta Shunmugavelu, Minakshi Deshmukh, Vaishali Chetan Maislos, Maximo Lieberman, Gabriella Segal Shimon, Ilan Stern, Naftali Nabriski, Dan Karnieli, Eddy Shehadeh, Naim Gonzalez-Galvez, Guillermo del Rosario Arechavaleta-Granell, Maria Ortiz, Rafael Margarito Violante Franco, Guadalupe Morales Gurieva, Irina Suplotova, Lyudmila Aleksandrovna Troshina, Ekaterina Ruyatkina, Ludmila Aleksandrovna Voychik, Emma Anatolievna Martsevich, Sergey Startseva, Maria A Seeber, Mary Elizabeth Badat, Aysha Ellis, Graham Altuntas, Yuksel Guler, Serdar Ulgen, Ender Delibasi, Tuncay Chetty, Tony Hart, Randy Janzen, Jeannette Labonte, Isabelle Lau, David Liutkus, Joanne O'Keefe, Dennis Padwal, Raj Ransom, Thomas P.P. Tytus, Richard Weisnagel, Stanley John Adler, Jay Aqua, Keith Aronoff, Stephen L Bedel, Gary W. Blevins, Thomas Craig Blumenau, Joe Brockmyre, Andrew Peter Call, Robert S Canadas, Rafael Chaykin, Louis B Cohen, Kenneth Conrow, Jeffrey Keith Davis, Matthew G Downey, H Jackson Drosman, Steven Richard Duckor, Steven Farmer, H. Frank Farrell, James Fehnel, Stephen Finneran, Matthew Patrick Forbes, Ray Forker, Alan Fredrick, Mark Fujioka, Ken Geller, Steven Andrew Gill, Santosh Glaser, Linda Greco, Susan Neims Greenway, Frank Lyons Harper, Wayne Herman, Lee Hoekstra, John Ingebretsen, Richard Ison, Rodney Jain, Rajeev K Kaplan, Roy Kaster, Steven Richard Haase, Gregory A Kerzner, Boris Kirstein, Judith Lee Koltun, William Krieger, Diane R Lewis, Cora Elizabeth Madder, Robert Marple, Richard N McDermott, Edward J Mello, Curtis John Miller, Alan B. Mullen, Julie Nardandrea, John O'Neil, Patrick Pi-Sunyer, F. Xavier Pucillo, Ronald M Rhee, Chanhaeng Redrick, Scott Pardini, Aaron Rothman, Jeffrey Rubino, Domenica Marie Sellers, Gladstone Smith, Timothy Byars, William David Soufer, Joseph Sussman, Allen Michael Patrick, Kyle Schramm, Erich Lloyd Van Cleeff, Martin Berg, Saul Reuel Wyatt, Holly Roxanna Simon, James Alan
Source :
The Lancet; April 2017, Vol. 389 Issue: 10077 p1399-1409, 11p
Publication Year :
2017
Abstract
Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.
Details
Language :
English
ISSN :
01406736 and 1474547X
Volume :
389
Issue :
10077
Database :
Supplemental Index
Journal :
The Lancet
Publication Type :
Periodical
Accession number :
ejs41527980
Full Text :
https://doi.org/10.1016/S0140-6736(17)30069-7